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Abstract
Background: Emergency Departments (EDs) are beginning to notify their physicians of patients 
reporting chronic noncancer pain (CNCP) who frequent EDs, and are suggesting that the 
physicians not prescribe opioids to these patients.
Objectives: We hypothesized that this intervention would reduce both the number of opioids 
prescribed to these patients by their ED physicians and the number of these patients’ return visits 
to the ED.
Methods: We conducted a randomized controlled trial of this intervention in 13 electronically 
linked EDs. Patients eligible for the study were characterized by CNCP, lacked evidence of sickle 
cell anemia and suicide ideation, and made frequent (>10) visits to the EDs over a 12-month 
period. We randomly assigned 411 of these patients to either an intervention group or a control 
group. Our intervention comprised both an alert placed in eligible patients’ medical files and 
letters sent to the patients and their community-based providers. The alert suggested that 
physicians decline requests for opioid analgesic prescriptions and instead refer these patients to 
community-based providers to manage their ongoing pain.
Results: During the 12 months after randomization, patients in the intervention and control 
groups averaged 11.9 and 16.6 return visits, and received prescriptions for opioids on 16% and 
26% of those visits, respectively. Altogether, patients in the intervention group made 1033 fewer 
return visits to the EDs in the follow-up year than those in the control group.
Conclusion: This intervention constitutes a promising practice that EDs should consider to 
reduce the number of visits made by frequent visitors with CNCP.
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INTRODUCTION
Deaths due to the misuse of opioids nearly doubled in the 10-year period ending in 2007 (1). 
The age-adjusted death rate from unintentional poisoning in the United States increased by 
125% from 1999 to 2007, and prescription drugs have accounted for at least 90% of the 
deaths over that period (2). Between 1999 and 2008, the rate of admissions to drug treatment 
facilities reporting pain medication abuse increased by 400% (3). Further, between 1999 and 
2006, the use of prescription opioids quadrupled in the United States (4). There is a linear 
relationship between sales of prescribed opioids and mortality attributable to drug poisoning 
(5). In 2012, about 2.6% of Americans aged 12 years and over reported that they had used 
prescription psychotherapeutic drugs in the past year that had not been prescribed to them, 
and about 8000 people develop opioid addiction daily (6,7). In 2006, the nonmedical use of 
oxycodone and hydrocodone accounted for 120,000 emergency department (ED) visits, and 
rates of ED visits related to narcotic analgesics rose by 155% between 2004 and 2009 (8,9). 
The total costs of prescription opioid abuse to society as of 2009 were estimated at $55.7 
billion, of which $25.0 billion were borne by the health care system, $25.6 billion related to 
workplace costs, and $5.1 billion were associated with costs related to criminal justice (10).
Deaths attributable to opioid analgesics are increasingly recognized as preventable (9). 
Hospital EDs, which are a source of prescription drugs that patients may then either misuse 
or provide to others, constitute one appropriate target for prevention efforts (11). In 
response, some EDs have begun to develop a strategy to notify their providers of patients 
who frequently visit EDs seeking treatment for chronic noncancer pain (CNCP). The 
strategy typically suggests that the ED provider decline the patients’ requests for controlled 
substances and instead advise them to seek help managing their chronic pain from a 
community-based primary care provider (12). Given that repeat visitors often appear at EDs 
due to pain-related symptoms, they are at elevated risk of being prescribed medications 
associated with increased risk of injury (13,14). One study found that repeat visitors with 25 
or more visits in the prior year had five times the odds of having a past prescription for an 
opioid compared to individuals with no history of an ED visit in the prior year (15).
Two previous evaluations of ED-based interventions of this nature have noted substantial 
reductions in ED visits, one by 40.9% and the other by 71.6% (16,17). However, both used 
single-group designs with very small samples (36 and 24 patients, respectively). In addition, 
unpublished data available from studies of interventions that have been conducted in 
Olympia and Spokane, Washington have reported reductions in ED visits of 55% and 48%, 
respectively (18,19). However, this approach to the care of patients with CNCP in EDs has 
yet to be subjected to a formal evaluation.
In this article we present the results of a randomized controlled trial of an intervention 
designed to reduce both the number of opioids prescribed by ED physicians to repeat ED 
visitors reporting CNCP, and the number of hospital visits made by these patients. The 
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intervention in the study consisted of an alert placed in patients’ medical files and a letter 
sent to the patients and their community-based providers. The alert suggested that physicians 
decline requests for repeat opioid prescriptions and instead refer these patients to 
community-based providers to manage their ongoing pain. The letter informed patients and 
their community-based providers of this protocol. We hypothesized that patients in the 
intervention group would manifest both fewer return visits to the EDs and fewer 
prescriptions for opioid medications from study ED providers, compared to patients in the 
control group.
MATERIALS AND METHODS
Setting
The Injury Prevention Research Center of the University of North Carolina at Chapel Hill 
conducted this study in collaboration with Carolinas HealthCare System (CHS), located in 
Charlotte, North Carolina. CHS constitutes one of the largest public hospital systems in the 
United States, and contributed 13 of their electronically net-worked EDs to the study. The 
EDs participating in the study were located in five contiguous counties that included both 
metropolitan and rural areas.
Intervention
The intervention for this study comprised two components, of which the first consisted of an 
alert placed in patients’ electronic medical records. The alert informed pertinent ED staff 
that the patients were enrolled in the study’s intervention group, that a multidisciplinary 
review team at CHS had determined that the patients had made multiple visits to various 
CHS EDs for treatment of CNCP, and that it was in the patients’ best interests to receive 
treatment for their pain from a community-based provider. The alert continued by 
recommending that the ED provider should suggest to these patients that they visit a 
community-based primary care provider, pain clinic, or other facility such as a drug 
treatment or mental health facility. In addition, we instructed ED staff to give each of these 
patients a list of appropriate community resources, which the study provided to ED staff. 
The intervention also invited the ED provider not to prescribe opioid medications to the 
patient, and not to write prescriptions for any medications that the patient reported as lost or 
stolen. However, the alert also stated that the provider should follow a customary standard of 
care for patients presenting with acute pain, and that the provider’s clinical judgment should 
ultimately determine the nature of the care offered for both acute and chronic pain.
The second component of the intervention was a letter sent to both patients and their 
community-based providers. The letter informed patients that a group of medical providers 
affiliated with CHS had determined that they should no longer receive opioid pain 
medication for their CNCP from a CHS ED, and their pain would best be treated by a 
community-based provider. However, to avoid discouraging use of the ED for medical 
emergencies, the letter encouraged the patient to return to the ED for assistance with other 
medical needs. The letter also included a phone number that patients could use to call with 
any concerns related to the letter and informed them that we had mailed a similar letter to 
their primary care provider if one was listed in their electronic medical record. Copies of the 
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text of the electronic alert and the letters we sent to both the patients and their primary care 
providers are available from the first author upon request.
Patients enrolled in the control group did not receive either of the intervention components.
Participant Selection
Study subjects for this randomized controlled trial were identified in a step-wise fashion. We 
initially identified patients by reviewing electronic medical charts over a 12-month period 
from October of 2010 to September of 2011. Patients eligible for the study were between 18 
and 89 years of age and had visited CHS’ EDs more than 10 times over this period. As we 
found no established definition of “frequent” ED use, we selected 11 visits as an arbitrary 
threshold to include patients who had visited the ED almost monthly (20). This initial 
process yielded a potential sample pool of 1539 patients. To secure the sample for our study, 
we reviewed each of these patients’ medical records in a downward hierarchical fashion 
beginning with those who had made the largest number of visits.
During an 8-month period beginning in October of 2011, a clinical staff team reviewed and 
summarized every visit made by each patient. This summary included the presenting 
complaint, discharge codes, all physicians’ notes related to acute and chronic pain, and all 
pain medicines either administered in the ED or written as a prescription. Key terms that we 
utilized in our review of physicians’ notes included chronic or acute pain; injury; drug abuse, 
misuse, or addiction; cancer; and suicide or self-harm.
Inclusionary criteria for the study comprised patients who, in at least two of these visits, had 
a discharge code related to nonspecific, subjective pain, which we defined as back or neck 
pain, headache or migraine, arthritis or joint pain, chronic pain syndrome, or generalized 
pain. We also applied a set of exclusionary criteria, namely, patients who had preexisting 
sickle cell anemia or a diagnosis of cancer (other than nonmelanoma skin cancer), to ensure 
that we would do nothing to harm these vulnerable populations by suggesting that their 
providers deny them the opioid analgesics they might need to manage their pain. We also 
excluded patients who had not visited the ED within the 120 days preceding the end of the 
eligibility period, reasoning that they may have moved out of the area or found an alternate 
source for pain management. A committee of eight medical staff who represented a variety 
of medical professions experienced with responding to opioid-abusing patients, and who 
comprised ED providers, a dentist, a pharmacist, and an orthopedist, reviewed each chart 
summary. They then voted as to whether to exclude any patients who were potentially 
eligible for the study. This committee discussed the records of any patients whose vote was 
not unanimous, and a majority vote determined whether the patient was ultimately eligible 
for enrollment.
As specified in Figure 1, we excluded 382 (48%) of 793 patients identified with the highest 
number of ED visits, who in aggregate had made an average of 14 visits (SD = 18) to at least 
one of CHS’ EDs in the previous 12 months. Of these, 107 had not visited any of CHS’ 
constituent EDs in the 120 days prior to the conclusion of the eligibility period. Subsequent 
to our initial enrollment procedures, but prior to random assignment, we learned that one of 
CHS’ EDs had previously instituted a set of protocols similar to ours, and we dropped the 22 
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patients identified as having been enrolled in that plan. Additionally, because two CHS ED 
facilities chose not to participate in the study, we also excluded 188 patients who made the 
majority of their visits during the eligibility period to these EDs. We excluded an additional 
49 patients because they lacked a diagnosis of chronic pain or because their records provided 
evidence of any of the other reasons specified in this figure, including suicide attempts or 
ideation. We excluded these latter patients because we were concerned that our intervention 
might precipitate suicidal behavior among patients who were already so disposed.
Using a Web-based random number generator, the first author randomly assigned 204 and 
206 patients to the intervention and control groups, respectively, within four consecutive 
cohorts over 51 days beginning in May 2012 and continuing through August of that year. 
During the course of the 12-month intervention for each cohort, we identified 13 and 16 
patients in the intervention and control groups, respectively, whom we learned, from an 
ongoing review of their medical records, had received a new cancer diagnosis or had 
attempted or considered suicide. We then removed these patients from the study because 
they no longer met its eligibility criteria, and did not follow them further. However, these 
patients continued to provide data for our intent-to-treat study until the date they received 
either of these diagnoses. Five participants from the intervention group were excluded after 
randomization but prior to the activation of the intervention because they manifested 
evidence of exclusionary criteria within this period. We completed data collection for all 
subjects in July of 2013. See Figure 2 for a schematic of the study timeline.
Our calculations indicated that a sample size of 204 and 206 patients in the intervention and 
control groups, respectively, would have 66% effect to detect a difference in means between 
the two groups of 2.5 visits, assuming a common SD of 10.60 using a two-group t-test (p < 
0.05) (21,22). The estimation was based on the assumption that the intervention would result 
in a 37% reduction in ED visits in the intervention group. We calculated the SD using the 
SD of total hospital visits for the entire study population during the baseline period.
Because we were primarily interested in changing ED providers’ prescribing practices, we 
secured consents (response rate = 96%) only from CHS’ ED providers. All study protocols 
were approved by the Institutional Review Boards (IRBs) of both Injury Prevention 
Research Center of the University of North Carolina at Chapel Hill and Carolinas 
HealthCare System, which granted us waivers of active patient consent because they 
determined the risk of harm to patients was no more than minimal, that patients would never 
be denied care they needed, and that their data would be fully de-identified before CHS 
shared the data with investigators at Injury Prevention Research Center of the University of 
North Carolina at Chapel Hill. The IRBs further determined that we could not reasonably 
have conducted our study had patient-level consent been required.
Methods and Measurements
The primary goals of the intervention were to reduce provider prescribing of opioids to 
frequent ED visitors and to improve CNPC. Due to data constraints, we were unable to 
directly measure the effect of the intervention on providers’ prescribing behaviors. However, 
we did measure the number of visits study subjects made to CHS EDs for any reason and the 
number of written prescriptions for opioid analgesics they received from ED providers that 
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will serve as proxy outcome measures in the analyses. We identified opioid prescriptions 
from patients’ electronic medical records employing charge codes and National Drug 
Classification codes. We also collected descriptive data concerning patients enrolled in the 
study, and characteristics of their ED visits during the year prior to the study’s onset, that we 
used to determine initial eligibility. Descriptive data included gender, age, payer type, 
primary complaint at admission by patient, and discharge diagnosis by physician. We 
categorized primary complaints and discharge diagnoses related to CNCP as neck pain, 
headache or migraine, chronic pain, generalized pain, or other, the International 
Classification of Diseases, Ninth Revision (ICD-9) codes for which may be found in Table 
1. We also used ICD-9 codes to identify patients’ primary complaint at admission and 
physician discharge diagnosis.
Analysis
We began by examining the patient-level variables specified above at baseline, both to 
describe our sample and to determine the success of randomization in achieving equivalency 
across the study’s two groups. To that end we used bivariate analyses to detect any 
differences in baseline characteristics between study groups. We also employed Wilcoxon-
Mann Whitney tests to detect differences in continuous variables between groups, and 
Mantel-Haenszel chi-squared statistics to detect differences in categorical variables between 
groups.
To address the study’s two hypotheses, we compared differences between the intervention 
and control groups in the number of 1) ED visits patients made and 2) prescriptions for 
opioids they received from emergency physicians. In our initial analysis of these hypotheses, 
we used t-tests to determine any difference between groups. We then ran two Poisson 
regressions, one crude and one adjusted, for both hospital visits and prescribed opioids. We 
adjusted the multivariate models for participant race and baseline opioid prescriptions 
because they were found to differ significantly between groups at baseline. We assessed each 
model for over-dispersion and, if it was present, used a negative binomial model instead 
(23). Because we could not assume independence between patient-level observations, insofar 
as patients could be clustered both within EDs and providers, we employed robust standard 
errors for repeated subjects, with an equi-correlated covariance structure in all models. We 
established a threshold of significance as p < 0.05, and conducted all analyses using SAS 
Version 9.3 (Cary, NC).
RESULTS
A total of 406 patients were included in the final analysis, 200 and 206 randomized to the 
intervention and control groups, respectively. As displayed in Table 2, the average patient in 
both study groups was 39 years old, female, and white. However, we did find a significantly 
higher (p = 0.004) proportion of white patients in the control than the intervention group.
Overall, the study’s subjects made a total of 9059 ED visits during the preactivation period, 
of which patients in the intervention and control groups made 4544 and 4515 visits, 
respectively. The most common chronic pain-related complaint was neck pain for patients in 
the intervention group, and headache or migraine for those in the control group. Medicaid 
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paid for nearly all of the hospital visits for both groups. During the 12-month baseline 
period, patients averaged 22 ED visits and were prescribed an average 0.27 opioid 
prescriptions (0.26 vs. 0.28 for the intervention and control groups, respectively) per hospital 
visit: that is, they received an opioid prescription at discharge in slightly over one visit out of 
four. However, during this period, patients in both the intervention and control groups were 
administered opioids while being treated in the ED for an average of 91% of their visits 
(confidence intervals [CIs] ± 1.9 and ± 1.7, respectively, ns). During the follow-up period, 
our intent-to-treat analysis found that patients in the intervention (n = 200) and control (n = 
206) groups were administered opioids in 29% (95% CI 0.27–0.31) and 45% (95% CI 0.43–
0.47) of their visits, respectively, and received prescriptions for opioids in 16% (CI 0.15–
0.18) and 26% (CI 0.25–0.28) of their visits, respectively.
Table 3 displays the unadjusted comparisons of the study’s two key outcomes, disaggregated 
by group. As expected, during the study period, patients in the intervention group made 
significantly fewer hospital visits and received fewer prescribed opioids from emergency 
physicians than control patients. On average, an intervention patient made nearly five fewer 
hospital ED visits than did controls (p < 0.001). In Figure 3 we graphically display the 
disparity between visits made by intervention and control patients over the follow-up period, 
disaggregated into 13 28-day temporal increments. Altogether, 18 patients (11 in the 
intervention and 7 in the control group, ns) made no return visits to EDs during the study 
period. The median number of return visits in the intervention and control groups was 9.0 
(range = 0 to 111) and 13.5 (range = 0 to 106), respectively.
Despite randomization, participant race was significantly different between groups. Because 
this difference may have confounded the crude estimate, we adjusted our regression models 
for this variable. Table 4 shows the unadjusted and adjusted rate ratios for the main effect 
regression models. After adjusting for differences in race and baseline prescription opioids, 
and as compared to those in the control group, patients in the intervention group had 0.69 
times the rate of hospital visits (95% CI 0.57–0.84; p < 0.0002,) and 0.57 times the rate of 
prescribed opioids (95% CI 0.46–0.70; p < 0.0001) during the 1-year follow-up period.
DISCUSSION
The results of our study supported our hypotheses that our ED-based care coordination plan 
targeting frequent visitors with CNCP would decrease in the EDs that participated in the 
study, the number of both the patients’ repeat visits, and the prescriptions they received for 
opioid analgesics. We note that these reductions were clinically as well as statistically 
significant, insofar as they represented reductions of 28% and 38% in the number of return 
visits by and opioids prescribed to patients in the intervention and control group, 
respectively.
We were surprised to discover that during the 12-month eligibility period prior to random 
assignment, the frequent ED visitors in our sample received prescriptions for opioid 
analgesics in only one visit out of four, which seemed to us an insufficiently consistent 
incentive to warrant their return visits. However, we also noted that patients in both the 
intervention and control groups were administered opioids in the ED, prior to their 
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discharge, in almost all (i.e., 91%) of their visits. We thus surmise that patients’ primary 
incentive for continuing ED visits was to receive parenteral or oral opioids in the ED itself. 
If so, this finding suggests that the patients in our sample were unlikely to have visited EDs 
to secure prescriptions for opioids that they subsequently intended to divert.
As expected, the average number of prescriptions for opioids that patients in the control 
group received per visit during the baseline and follow-up year, 0.27 and 0.26, respectively, 
remained largely static. However, a visual inspection of Figure 2 reveals a slight downward 
trend in the monthly increments assessed in prescriptions for both the intervention and 
control groups. This decline could be attributed to several factors, including a secular trend 
toward more constrained opioid prescribing practices. It is also possible that as the 
intervention progressed, providers became more likely to decline opportunities to prescribe 
opioid analgesics to their CNCP patients. To explore the potential of a provider learning 
effect over time on these prescribing behaviors, we conducted a post hoc analysis of the 
association between enrollment cohort and number of prescriptions written and found no 
association. The decline we noted may also be attributable to contamination effects, as 
providers sensitized by the flags placed in the files of intervention group patients began to 
consider these warnings when they treated other frequent visitors reporting chronic pain, 
including those in the control group. However, we think the most likely factor to which the 
declines we noted can be attributed is regression to the mean from extreme values; other 
studies have reported that even in the absence of any intervention, the number of ED visits 
made by frequent visitors in any given year tend to decrease in the following one, and thus 
this status may be temporary (24–26).
From the study’s outset we were aware that the EDs in the medical system that served as our 
study site would be unable to provide continuity of care to uninsured patients enrolled in the 
intervention group who lacked community-based health providers and thus, potentially, the 
means to pay for their services. Although we gave consideration to compensating the 
providers to whom the EDs’ providers might refer these patients, study resources were 
inadequate to do so. We were also aware that other hospital systems that might adopt an 
intervention similar to ours would also be unlikely to have discretionary funds that they 
could offer these patients’ community-based providers, and thus believe that our approach is 
reflective of the constraints that EDs generally face. However, the overwhelming majority 
(>99%) of visits made by study patients were supported either by Medicare, Medicaid, or 
commercial or managed care plans, a finding that is consistent with that reported by other 
studies of frequent ED visitors (26). We thus expect that almost all the patients in our 
intervention group should have had access to a community-based provider, although some of 
those covered by Medicaid may have experienced challenges in scheduling outpatient 
appointments or in finding a provider who would accept their insurance. That said, we 
cannot exclude the possibility that we may have harmed some of the patients in our 
intervention group because they were not administered or prescribed appropriate 
medications to assist them in managing their pain.
We also note that the process we used to screen out patients as ineligible for the study was 
both labor intensive and expensive, insofar as it required a close, ongoing scrutiny of 
patients’ discharge codes and a content analysis of their providers’ chart notes to identify 
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those who either developed a diagnosis of cancer or sickle cell anemia, or who gave 
evidence of suicide ideation or attempts. As approved by our institutions’ IRBs, our study 
protocols also required that summaries of each patient’s records be prepared and reviewed 
by a team of health professionals to ensure that we did not enroll patients who met any 
exclusionary criteria. We suspect, however, that our procedures, which involved a formal 
data abstraction process from both coded and textual medical records followed by a review 
by eight medical staff, may have been unnecessarily cautious. Perhaps an ongoing chart 
review by one or two medical experts would suffice, as long as it included an inspection of 
text available in eligible patients’ medical records to verify that no disqualifying criteria are 
present. We are concerned that staff in EDs that seek to replicate our protocols may not go to 
sufficient lengths to ensure that patients with diagnoses of cancer-related pain, or those who 
manifest either suicide ideations or attempts, are exempted from the intervention. In 
addition, we hope that other EDs that may consider our protocols will have the means that 
CHS lacked to refer CNCP patients who lacked primary care providers—and particularly 
those demonstrating evidence of suicide ideation or attempts—to specific community-based 
health professionals who are trained to manage their chronic pain needs. We believe that the 
resource guide we provided these patients was adequate but clearly suboptimal.
We also note several issues related to our study’s methodology. The average number of visits 
our study’s subjects made to the ED, 22.3, was very high - almost twice a month over the 
course of the initial 12-month period of eligibility determination. Although there is no 
standard definition for “frequent ED use,” the threshold of four visits per year has appeared 
frequently in the literature, and one empirical study has defined “highly frequent use’” as at 
least 18 visits per year (20,26–28). As mentioned earlier, we deliberately selected those 
patients who had visited CHS’ EDs most frequently to maximize our power to detect 
differences in return visits between our intervention and control groups. Other EDs serving 
smaller numbers of frequent visitors with CNCP, who average fewer numbers of visits, may 
not fully replicate our results.
Limitations
We do not know how the providers who treated the subjects in our intervention group used 
the flags on their patients’ charts. Some may have discussed the alert with their patients, 
whereas other may not. Nor do we know if these patients understood the letters we sent to 
inform them of the intervention, or whether they talked about their plan with their 
community-based providers. Thus, we are unsure whether their behavior changed as a result 
of their providers’ behaviors, their own awareness of the content and implications of the 
intervention, or some combination of both. Insofar as only 5.5% of patients in the 
intervention group returned to the ED at least once after we sent our initial letters informing 
them of the intervention, it seems likely that changes in providers’ prescribing behaviors 
made a significant contribution to the outcomes noted.
Subjects in the intervention group had many alternatives to the services they received in 
CHS’ EDs. Charlotte, the large metropolitan area in North Carolina that served as the site 
for our study, has other hospital systems whose records are not linked to those of CHS; 
patients could also have sought medical care in any of those other facilities, some of which 
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are located in South Carolina, across the nearby state line. Patients may also have secured 
opioid analgesics from their primary care providers. Thus, patients in our intervention group 
may have compensated for what they may have perceived as denial of care by seeking 
medical attention elsewhere.
Other limitations to our study should be considered. First, the heterogeneity of the counties 
that CHS’ systems served - one urban, several quite rural - increases uncertainty about the 
external validity of our study’s findings; that is, whether they would likely be replicated in 
entirely urban or rural environments. Also potentially limiting our study’s external validity is 
the insurance status of our patient population; as indicated in Table 1, almost all were 
covered by some form of insurance (about two-thirds by Medicaid and one-fifth by 
Medicare). Hospital EDs serving populations characterized by very different payer 
mechanisms may have different experiences with the intervention we tested.
As a final study limitation, we recognize that our patients were clustered both within and 
across both CHS’ constituent ED providers, who themselves may have served multiple EDs. 
It is also possible that patients could have been clustered within providers within the same 
visit, if more than one attended to a particular patient. Rather than attempting to control for 
this multiple and complex clustering, we chose simply to compare the patients in our 
intervention and control groups as if they were statistically independent of one another. 
Thus, our providers may have become sensitized over time to the opioid-seeking behaviors 
of all the frequent visitors with CNCP whom they treated. If that is indeed the case, our 
findings may be considered conservative— that is, the true difference between providers’ 
prescribing behaviors related to patients in the intervention and control groups would have 
been attenuated. This may also serve to explain two unexpected findings related to our 
control group: first, that the proportion of control patients who were administered opioid 
analgesics in the ED decreased from 91% of their visits at baseline to 45% over follow-up, 
and second (as depicted in Figure 3), that the number making return visits to the ED 
decreased in each 28-day period. On the other hand, this reduction could also have 
represented providers’ increasing wariness over time in regards to responding to the 
articulated pain management needs of this cohort of frequent visitors.
CONCLUSION
Our study has demonstrated the positive effects of our intervention on repeat visits and 
opioid analgesics prescribed to a population of very frequent visitors to a set of 
electronically linked EDs who are characterized by CNCP. Hospital systems considering 
adopting a similar program should do so with the key proviso that frequent visitors be 
informed that the ED continues to be available to them to manage health concerns unrelated 
to chronic pain. Frequent ED visitors constitute a highly heterogeneous group who suffer 
from a variety of physical and psychiatric comorbid conditions, and their access to prompt 
medical attention to treat these conditions must not be curtailed, particularly as their 
conditions may not be adequately met by their primary providers (20,24,25,27).
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ARTICLE SUMMARY
1. Why is this topic important?
Some patients with complaints of chronic noncancer pain (CNCP) visit 
emergency departments (EDs) frequently, seeking controlled substances either 
to manage their condition or to use or divert for nonmedical reasons.
2. What does this study attempt to show?
In this randomized controlled trial, we investigated the effects of an alert 
placed in the electronic files of patients enrolled in the intervention group, 
notifying their providers that they were frequent ED visitors with CNCP 
whose needs for pain management would best be managed by a community-
based provider. We examined whether the alerts would reduce the number of 
these patients’ return visits to the ED, as well as the number of visits on 
which they were prescribed controlled substances.
3. What are the key findings?
During the 12 months after randomization, patients in the intervention and 
control groups averaged 11.9 and 16.6 return visits, and received prescriptions 
for opioids on 16% and 26% of those visits, respectively.
4. How is patient care impacted?
The alert specified substantially reduced participating EDs’ burden of patients 
who frequently visited the ED seeking care for CNCP that was more 
appropriately provided in community-based medical settings.
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Figure 1. 
Flow chart of patients initially eligible to participate in the study. COPD = chronic 
obstructive pulmonary disease; ED = emergency department.
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Figure 2. 
Study timeline.
Ringwalt et al. Page 15
J Emerg Med. Author manuscript; available in PMC 2019 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Number of emergency department visits per 28-day period.
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Table 2.
Baseline Patient Characteristics
Intervention
(n = 200)
Control
(n = 206)
Total
(n = 406) p-Value
Age
 Mean (SD) 38.98 (11.2) 39.70 (12.2) 39.34 (11.7) 0.78
Gender
 Male (%) 81 (40.5) 68 (33.0) 149 (36.7) 0.12
 Female (%) 119 (59.5) 138 (67.0) 257 (63.3)
Race
 White (%) 126 (63.0) 158 (76.7) 284 (70.0) 0.004
 Black (%) 73 (36.5) 47 (22.8) 120 (29.6)
 Other (%) 1 (0.5) 1 (0.5) 2 (0.5)
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Table 4.
Main Effect Models for Main Outcomes
Rate Ratio 95% CI p-Value
Number of ED visits*
 Unadjusted 0.717 0.59–0.88 0.0012
 Adjusted† 0.690 0.57–0.84 <0.0002
Number of opioid prescriptions‡
 Unadjusted 0.570 0.46–0.71 <0.0001
 Adjusted† 0.569 0.46–0.70 <0.0001
CI = confidence interval; ED = emergency department.
*Negative binomial model used to account for over-dispersion.
†Adjusted for participant race and baseline opioid prescriptions.
‡
Poisson model.
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